Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials

Background: ATX-101 (deoxycholic acid) significantly reduced submental fat (SMF) severity in two 24-week Phase 3 studies (REFINE-1 and REFINE-2). Objectives: The aim of this study was to evaluate the durability of effect and long-term safety of ATX-101. Methods: REFINE study patients who maintained >= 1-grade improvement on the Clinician-Reported SMF Rating Scale (CR-1 responders) 12 weeks after their last REFINE treatment were eligible for enrollment in this multicenter, double-blind, nontreatment, long-term, follow-up study (NCT02163902). The primary endpoint was CR-1 response at Years 1, 2, and 3. Patient-reported satisfaction, psychological impact, and adverse events were monitored. Results: In total, 224 patients (ATX-101, n=113; placebo, n=111) were enrolled. Maintenance of CR-1 response was significantly better in the ATX-101 group than in the placebo group at Year 1 (86.4% vs 56.8%; P<0.001), Year 2 (90.6% vs 73.8%; P=0.014), and Year 3 (82.4% vs 65.0%; P=0.03). Most (74%) ATX-101treated patients satisfied at 12 weeks remained satisfied at Year 3. Significant reductions from baseline in psychological impact scores were sustained through Year 3 (P<0.001). No new treatment-related adverse events were reported. Conclusions: Improvements in submental contour achieved with ATX-101 are maintained for 3 years in most patients. No new safety signals emerged.

Automated summary

ATX-101 significantly reduces submental fat severity and the improvement is maintained for 3 years in most patients. Patient satisfaction and psychological impact scores remain stable over time, with no new treatment-related adverse events reported.